Quick Stats
Listing Price
83
(5.06%)
Subscription
7.27x
Allotment Status
Out
Last Updated
27-03-2026 10:46 AM
Gaudium IVF and Women Health IPO – Live GMP, Review & Analysis
Gaudium IVF and Women Health IPO GMP Today - ₹-4 (-5.06%)
Last updated: 27-02-2026 10:00 AM
Grey Market Premium Analysis
As of today, the latest Grey Market Premium (GMP) for Gaudium IVF and Women Health IPO is ₹-4. Considering the upper price band of ₹79, the estimated listing price is ₹75 (Cap Price + GMP). This indicates a listing gain of -5.1% per share. The GMP trend has been Down over the last 3 days.
GMP Trend Analysis
| Date | GMP Price | Est. Listing Gain | Trend |
|---|---|---|---|
| 27-02-2026 | -4 | ₹-756 | Neutral |
| 26-02-2026 | -4 | ₹-756 | Down |
| 25-02-2026 | 0 | ₹0 | Down |
| 24-02-2026 | 5 | ₹945 | Down |
| 23-02-2026 | 8.5 | ₹1,606.5 | Up |
| 22-02-2026 | 8 | ₹1,512 | Neutral |
| 21-02-2026 | 8 | ₹1,512 | Neutral |
| 20-02-2026 | 8 | ₹1,512 | Down |
| 19-02-2026 | 10 | ₹1,890 | Neutral |
| 18-02-2026 | 10 | ₹1,890 | Neutral |
| 17-02-2026 | 10 | ₹1,890 | Neutral |
Gaudium IVF and Women Health IPO Date, Price Band & Lot Size
Price Band
₹75-79
Lot Size
189 shares
Cutoff Investment
14931
Promoter Holding
Open
Feb 20, 2026
Close
Feb 24, 2026
Allotment Date
Feb 25, 2026
Listing Date
Feb 27, 2026
Issue Size
165
Gaudium IVF and Women Health IPO Review: Business Model
*This section provides a detailed description of Gaudium IVF and Women Health IPO's business operations and market position.
Gaudium IVF and Women Health IPO Financial: Revenue, Profit & Margins
Key financial metrics over recent years.
*Values in Cr
Revenue
₹71 Cr
Net Profit
₹19 Cr
EBITDA
₹28 Cr
ROE
41.71%
ROCE
53.68%
Debt/Equity
0.19x
PAT Margin
27.05%
Peer Comparison
Healthcare Services (Specialized & Multi-Specialty) • FY25
| Company | Revenue (₹ Cr) | PAT (₹ Cr) | EBITDA Margin | P/E | Market Cap (₹ Cr) | Comment |
|---|---|---|---|---|---|---|
Gaudium IVF and Women Health Limited (IPO Company) IPO Company | 71 | 19 | 40.8% | 22.99 | 575 | Specialized player focused exclusively on Assisted Reproductive Technology (ART) and women's health with a scalable hub-and-spoke model. |
Rainbow Children's Medicare Ltd | 1,544 | 238 | 34.8% | 54.00 | 12,850 | Leading pediatric and maternity healthcare chain with a significant and growing fertility (IVF) vertical. |
Jupiter Life Line Hospitals Ltd | 1,262 | 194 | 23.5% | 41.80 | 8,078 | Multi-specialty tertiary care provider with a strong regional presence in Western India, similar to Gaudium's expansion markets. |
Krishna Institute of Medical Sciences (KIMS) | 3,035 | 385 | 25.8% | 71.10 | 27,385 | Large-scale corporate hospital chain operating a high-volume model with comparable regional operational dynamics. |
Analysis & Interpretation
Gaudium IVF operates in a niche, high-margin segment compared to multi-specialty peers, which is reflected in its superior EBITDA margins relative to revenue. While peers like Rainbow and KIMS have significantly larger scale and revenue bases, Gaudium's specialized low-capex model allows for different profitability metrics. The IPO valuation appears to be at a discount to these established sector leaders in terms of P/E ratio, though the peers command a scarcity premium due to their size and track record.
Note: The peer group includes large multi-specialty and pediatric hospital chains as there are limited direct listed pure-play IVF peers in India. Financials are for FY25 to provide the most recent comparable data.
Source: Red Herring Prospectus (RHP) and Company Annual Financial Results (FY25).
This peer comparison is for informational purposes only and is based on publicly available financial data. It does not constitute investment advice or a recommendation to buy or sell any security.
IPO Objectives (Use of Funds)
Capital Expenditure
₹50.00 Cr(-)Funding the establishment of 19 new IVF centers to expand the company's network across India.
Debt Repayment
₹20.00 Cr(-)Repayment or prepayment, in full or part, of certain outstanding borrowings availed by the company.
General Corporate Purposes
Variable(-)To be utilized for general business requirements, subject to applicable regulatory limits.
Note: The Company will not receive any proceeds from the Offer for Sale (OFS component). Entire OFS proceeds will be received by the Selling Shareholder.
Source: Red Herring Prospectus (RHP)
For informational purposes only. Amounts are estimates and subject to final issue price.
Anchor Investor List & Allocation Details
Key institutional investors who subscribed to the IPO prior to opening.
| Investor Name | Category | Shares Allocated | Amount (Cr) |
|---|---|---|---|
| MERU Investment Fund PCC-CELL | FPI | 21,51,899 | ₹17.00 Cr |
| Sanshi Fund I | FPI | 15,82,278 | ₹12.50 Cr |
| Hornbill Orchid India Fund | FPI | 12,65,822 | ₹10.00 Cr |
| Carnelian India Multi Strategy Fund | AIF | 12,65,822 | ₹10.00 Cr |
SWOT Analysis (Pros & Cons)
Comprehensive analysis of Strengths, Weaknesses, Opportunities, and Threats.
Strengths
- •Operates scalable hub-and-spoke model with 35 centers across India
- •Integrated revenue streams from fertility treatments and in-house pharmacy
- •Consistent financial performance with ₹12.50 crore profit for recent period
- •Established clinical success rates of 58.74% in latest reporting period
Weaknesses
- •High employee attrition rate reported at 31% in recent period
- •Significant operational reliance on Promoter and limited embryology staff
- •Outstanding litigation regarding tax proceedings and consumer complaints
Opportunities
- •Plan to establish 19 new IVF centers using IPO proceeds
- •Growing demand for ART services due to declining fertility rates
- •Expansion of specialized male infertility and women's health services
Threats
- •Stringent compliance requirements under ART Act and PCNDT Act
- •Contingent liabilities of approximately ₹44.99 crore impacting financial stability
- •Reputational risks linked to clinical outcomes and success rates
IPO Video Analysis (External)
Detailed analysis of Gaudium IVF and Women Health IPO Analysis by market experts.
*Video embedded for convenience. Click the play button to load the content from YouTube.
Disclaimer: This video is shared for informational and educational purposes only. The views expressed are those of the respective creator and do not constitute investment advice.